NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).

在Line 61转基因小鼠模型中过表达人类野生型ASYN，NPT200-11（5 mg/kg; i.p.）导致视网膜ASYN病变的时间依赖性和逐步减少。NPT200-11减少了皮层中的α-突触核蛋白病变，减轻了相关的神经炎症（星形胶质细胞增生），使纹状体多巴胺转运体（DAT）水平正常化，并改善了运动功能[1]。